for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alliance Pharma plc

ALAPH.L

現在値

105.00GBp

変化

-0.60(-0.57%)

出来高

318,993

本日のレンジ

105.00

 - 

106.60

52週レンジ

71.56

 - 

123.00

∙ 約20分前の相場を表示しています。

価格

前日終値
105.60
始値
106.60
出来高
318,993
3か月平均出来高
16.75
高値
106.60
安値
105.00
52週高値
123.00
52週安値
71.56
発行済株式数
536.00
時価総額
562.80
予想PER
18.70
配当利回り
1.53

次のエベント

Half Year 2021 Alliance Pharma PLC Earnings Release

適時開示

その他

Alliance Pharma Sees FY Underlying PBT In Line With Market Expectations

Alliance Pharma FY Underlying Profit Before Tax Up 2%

Alliance Pharma Sees FY Pretax Profit To Be Marginally Ahead Of Market Consensus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alliance Pharma plcとは

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international. The Company's therapeutic areas of focus include cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology and travel health. The Company's product categories include prescription only medicines, over the counter medications, medical devices, cosmetics and nutritional supplements. The Company's products include SkinSafe, Lift Plus, AbsorbaGel, DeoGel, LaVera, ClearWay, Gelclair, ImmuCyst 81mg, Hydromol, MacuShield, Lypsyl, Anbesol Adult Strength Gel, MolluDab and Ashton & Parsons Infants' Powders.

業種

Biotechnology & Drugs

連絡先

Avonbridge House, Bath Road

SN15 2BB

United Kingdom

+44.1249.466966

https://www.alliancepharmaceuticals.com/

エグゼクティブリーダーシップ

David Cook

Independent Non-Executive Chairman of the Board

Peter Butterfield

Chief Executive Officer, Executive Director

Andrew Franklin

Chief Financial Officer, Executive Director

Stephen Kidner

Chief Scientific and Operations Officer

Janice Timberlake

Chief People and Infrastructure Officer

統計

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.2K
EPS (GBp)

2018

4.420

2019

4.990

2020

5.140

2021(E)

5.615
株価売上高倍率(過去12カ月)
71.62
株価売上高倍率(過去12カ月)
4.34
株価純資産倍率(四半期)
1.99
株価キャッシュフロー倍率
33.23
総負債/総資本(四半期)
50.55
長期負債/資本(四半期)
50.21
投資利益率(過去12カ月)
1.86
自己資本利益率(過去12カ月)
1.75

最新ニュース

最新ニュース

米連邦地裁、薬価引き下げ巡るトランプ政権の新規則を一時差し止め

米メリーランド州の連邦地裁は23日、1月1日からの薬価引き下げに向けてトランプ政権が制定した規則の実施を差し止める仮処分決定を下した。

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up